New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 22, 2013
10:00 EDTAPKT, STT, BMRN, MHK, MTRX, NXY, VIP, WCC, PCP, ASML, VIAB, GDP, RIMM, BKYFOn The Fly: Analyst Upgrade Summary
Today's noteworthy upgrades include: ASML (ASML) upgraded to Buy from Hold at ABN Amro... ASML (ASML) upgraded to Hold from Sell at Deutsche Bank... Bank of Kentucky (BKYF) upgraded to Outperform from Neutral at RW Baird... Goodrich Petroleum (GDP) upgraded to Outperform from Market Perform at BMO Capital... Precision Castparts (PCP) upgraded to Buy from Neutral at UBS... Research in Motion (RIMM) upgraded to Outperform from Sector Perform at Scotia Capital... Viacom (VIAB) upgraded to Buy from Neutral at Goldman... VimpelCom (VIP) upgraded to Overweight from Neutral at HSBC... WESCO (WCC) upgraded to Outperform from Neutral at Credit Suisse... Mohawk (MHK) upgraded to Outperform from Sector Perform at RBC Capital... State Street (STT) upgraded to Neutral from Underweight at JPMorgan... Nexen (NXY) upgraded to Hold from Sell at Canaccord... BioMarin (BMRN) upgraded to Buy from Hold at Stifel Nicolaus... Acme Packet (APKT) upgraded to Outperform from Market Perform at Northland Securities... Matrix Service (MTRX) upgraded to Overweight from Equal Weight at Stephens.
News For ASML;BKYF;GDP;PCP;RIMM;VIAB;WCC;VIP;MHK;STT;NXY;BMRN;APKT;MTRX From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
July 2, 2015
13:59 EDTBMRNNHS to wait on NICE to make call on PTC Therapeutics, BioMarin drugs
NHS England has set out its planned investment decisions for certain specialized services as part of its annual commissioning round. NHS England has agreed with the recommendations from CPAG that final funding decisions on the following two treatments should be made after NICE has concluded its Highly Specialized Technology Appraisal process: BioMarin Pharmaceutical's (BMRN) Vimizim for Morquio A Syndrome and PTC Therapeutics' (PTCT) Translarna for Duchenne muscular dystrophy. The decisions on those two drugs came among 39 proposed new investments that the group said were "carefully considered against the principles NHS England follows when making investment decisions." Reference Link
July 1, 2015
13:35 EDTVIABViacom sees advance ad commitments up 3%-4%, Variety says
Subscribe for More Information
10:00 EDTVIPOn The Fly: Analyst Upgrade Summary
Subscribe for More Information
09:28 EDTVIPOn The Fly: Pre-market Movers
Subscribe for More Information
08:57 EDTVIPVimpelCom upgraded to Buy from Neutral at BofA/Merrill
08:15 EDTVIPVimpelCom appoints Alexander Mutuschka as Group Chief Performance Officer
Subscribe for More Information
June 29, 2015
12:53 EDTBMRNSarepta NDA submission for eteplirsen done ahead of schedule, says Piper Jaffray
Piper Jaffray noted that Sarepta (SRPT) completed its rolling NDA submission for eteplirsen ahead of schedule and the firm believes that concurrent advisory committee meetings for its DMD drug and BioMarin's (BMRN) drisapersen could take place this fall. The firm has a Neutral rating and $20 price target on Sarepta and Overweight rating and $147 target on BioMarin.
08:36 EDTBMRNBioMarin announces FDA acceptance of drisapersen NDA
Subscribe for More Information
07:55 EDTMHKMohawk deal has signficant revenue synergies, says SunTrust
Subscribe for More Information
June 25, 2015
16:03 EDTBMRNBioMarin announces EMA validates MAA for drisapersen for treatment of DMD
Subscribe for More Information
June 23, 2015
07:49 EDTBMRNPTC Therapeutics risk lowered by symposium, says Oppenheimer
Subscribe for More Information
07:25 EDTBMRNPiper Jaffray to hold a summit
2015 Piper Jaffray Heartland Summit is being held in Minneapolis on June 23-24.
June 22, 2015
06:05 EDTGDPGoodrich Petroleum commences completion operations on 2 of 6 wells in TMS
Subscribe for More Information
June 19, 2015
10:28 EDTBMRNBioMarin slips after Baird breaks from pack with downgrade
Subscribe for More Information
10:00 EDTBMRNOn The Fly: Analyst Downgrade Summary
Subscribe for More Information
06:33 EDTBMRNBioMarin downgraded to Neutral from Outperform at Baird
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use